Immune-mediated necrotizing myopathy
MONDO:0016098Necrotizing autoimmune myopathy (NAM) is a rare form of idiopathic inflammatory myopathy characterized clinically by acute or subacute proximal muscle weakness, and histopathologically by myocyte necrosis and regeneration without significant inflammation.
Also known as: IMNM, NAM, anti-HMG-CoA myopathy, anti-SRP myopathy, autoimmune necrotizing myositis, immune myopathy with myocyte necrosis, necrotizing autoimmune myopathy
25 clinical trials for this condition and its sub-types, 17 tagged with Immune-mediated necrotizing myopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug shows promise for Long-Term control of rare muscle disease
Disease control By invitation onlyThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control By invitation onlyThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill could ease rare muscle disease symptoms
Disease control CancelledThis study is testing a drug called deucravacitinib in 10 adults with idiopathic inflammatory myopathies, a group of rare diseases that cause muscle inflammation and weakness. Participants will take one pill daily for 6 months. Researchers will track symptom changes and lab resul…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Phase 2/3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC